Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19

• Main Authors: Thomas J. Esparza (Author), Yaozong Chen (Author), Negin P. Martin (Author), Helle Bielefeldt-Ohmann (Author), Richard A. Bowen (Author), William D. Tolbert (Author), Marzena Pazgier (Author), David L. Brody (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

There remains an unmet need for globally deployable, low-cost therapeutics for the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Previously, we reported on the isolation and in vitro characterization of a potent single-domain nanobody, NIH-CoVnb-112, specific for the...